CareDx Announces Revised Timeline to Its Offer to Acquire Allenex

BRISBANE, Calif., Feb. 29, 2016 -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today announced a revised timeline to the recommended public offer to the shareholders of Allenex AB (Stockholm:ALNX, S+).

The previously announced timeline was based on both the approval from the Swedish financial regulator and the planned publication of the prospectus on February 29, 2016. Following recent changes in the working capital financing available to CareDx post closing of the offer that need to be reflected in the prospectus and the associated required additional reviews by CareDx’ Swedish and U.S. auditors, approval and publication of the prospectus is now expected to occur by March 7, 2016.  It is estimated that the offer will be completed in April 2016.

CareDx reserves the right to extend the acceptance period as well as to postpone the date of settlement.  CareDx will announce any further extensions or changes to the offer via press release in accordance with applicable laws and regulations.

About CareDx
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients. The company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate/severe acute cellular rejection.  CareDx is also developing additional products for transplant monitoring using a variety of technologies, including AlloSure™, its next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation. For more information, please visit: www.CareDx.com.

About Allenex AB
Allenex AB, headquartered in Stockholm, is a life sciences company that develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between the donor and the recipient of stem cells and organs. Allenex AB currently markets two key products; Olerup SSP, a set of HLA typing used prior to hematopoietic stem cell/bone marrow transplantation and organ transplantation, and XM-ONE®, the first standardized test used for crossmatching that identifies the presence of non-HLA antibodies strongly associated with rejection episodes and reduced kidney function after transplant.

Forward Looking Statements

This press release contains forward-looking statements including, but not limited to statements regarding the Company’s expectations regarding future potential, development and commercial activities. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward looking statements, including CareDx’s limited operating history and experience with developing new markets and that closing conditions may not be satisfied and the transaction may not be completed, as well as other risks stated in CareDx’s filings with the SEC located at www.sec.gov. CareDx disclaims any obligation to publicly update or revise any forward looking statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact
Molly Martell, CareDx, Inc.
T: +1 415-287-2397                                                  
E:  [email protected]

Investor Contact
Leigh J. Salvo, Westwicke Partners, LLC
T: +1 415-513-1281
E:  [email protected]